{
    "relation": [
        [
            "",
            "Placebo",
            "Sildenafil"
        ],
        [
            "Description",
            "placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks",
            "sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks"
        ]
    ],
    "pageTitle": "Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study) - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00763867?sect=Xl015&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042990177.43/warc/CC-MAIN-20150728002310-00330-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 861534327,
    "recordOffset": 861516903,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Placebo Drug: Sildenafil Interventions: Heart Failure Condition: Allocation:\u00a0Randomized; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Double\u00a0Blind\u00a0(Subject,\u00a0Caregiver,\u00a0Investigator); \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study Design: Interventional Study Type: Results First Received: April 4, 2013 \u00a0",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 Placebo \u00a0 \u00a0 Sildenafil \u00a0 STARTED \u00a0 \u00a0 103 \u00a0 \u00a0 113 \u00a0 COMPLETED \u00a0 \u00a0 98 \u00a0 \u00a0 101 \u00a0 NOT COMPLETED \u00a0 \u00a0 5 \u00a0 \u00a0 12 \u00a0 \u00a0 Baseline Characteristics \u00a0 Hide Baseline Characteristics Population Description Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. No text entered. Reporting Groups",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}